Inhibition of interleukin 1 (IL-1)-elicited leukocytosis and LPS-induced fever by soluble immune response suppressor (SIRS).
IL-1-induced leukocytosis was inhibited or blocked in a dose-dependent manner by SIRS, an antigen-nonspecific suppressive lymphokine, when administered intravenously or per os to CBA mice. Timing experiments showed that SIRS effectively inhibited the leukocytosis when administered within 30 minutes of the IL-1. An antipyrogenic activity of SIRS was observed in rabbits injected intravenously with LPS. SIRS, given intravenously in one or two doses, markedly reduced LPS-induced fever. SIRS (2000 units) was a more effective antipyretic agent than aspirin (3 mg/kg body weight, intramuscularly). The results suggest that SIRS may be a potential drug for use in IL-1-mediated disorders.
Zimecki
M
M
Department of Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Schnaper
H W
HW
Wieczorek
Z
Z
Webb
D R
DR
Pierce
C W
CW
D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D005260:Female; D005334:Fever / Q000139:chemically induced* / Q000503:physiopathology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D007958:Leukocyte Count; D007964:Leukocytosis / Q000139:chemically induced*; D051379:Mice; D008808:Mice, Inbred CBA; D009504:Neutrophils / Q000187:drug effects; D011135:Polysaccharides, Bacterial / Q000037:antagonists & inhibitors*; D011817:Rabbits; D013491:Suppressor Factors, Immunologic / Q000494:pharmacology*
D007375:Interleukin-1; D011135:Polysaccharides, Bacterial; D013491:Suppressor Factors, Immunologic; C013256:soluble immune response suppressor